Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?

Nicotine and Tobacco Research

Volumn 5, Issue 6, 2003, Pages 935-942

  David, Sean P ^a,c   Niaura, Raymond ^a   Papandonatos, George D ^a   Shadel, William G ^a   Burkholder, Gary J ^a   Britt, Dana M ^a   Day, Amy ^a   Stumpff, Jeffrey ^a   Hutchison, Kent ^b   Murphy, Michael ^d   Johnstone, Elaine ^d   Griffiths, Siân Elin ^d   Walton, Robert T ^d  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c BROWN UNIVERSITY   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; NICOTINE; PLACEBO;

ADULT; ANXIETY; ARTICLE; CASE CONTROL STUDY; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; IRRITABILITY; LONG TERM CARE; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELAPSE; SCORING SYSTEM; SMOKING CESSATION; SYMPTOMATOLOGY; TOBACCO DEPENDENCE; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ADULT; BUPROPION; DOPAMINE UPTAKE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; GANGLIONIC STIMULANTS; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NICOTINE; PLACEBOS; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE D2; SMOKING; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 9144252813     PISSN: 14622203     EISSN: None     Source Type: Journal    
DOI: 10.1080/14622200310001615295     Document Type: Article

References (54)

1. Ascher, J. A., Cole, J. O., Colin, J. N., Feighner, J. P., Ferris, R. M., Fibiger, H. C., Golden, R. N., Martin, P., Potter, W. Z., & Richelson, E., et al. (1995). Bupropion: A review of its mechanism of antidepressant activity. Journal of Clinical Psychology, 56(9), 395-401.
2. Benowitz, N. L. (1999). Nicotine addiction. Primary Care, 26(3), 611-631.
3. Blum, K., Braverman, E. R., Holder, J. M., Lubar, J. F., Monastra, V. J., Miller, D., Lubar, J. O., Chen, T. J., & Comings, D. E. (2000). Reward deficiency syndrome: A biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. Journal of Psychoactive Drugs, 32(Suppl. 1-4), 1-112.
4. Blum, K., Braverman, E. R., Wood, R. C., Gill, J., Li, C., Chen, T. J., Taub, M., Montgomery, A. R., Sheridan, P. J., & Cull, J. G. (1996). Increased prevalence of the Taq I A1 allele of the dopamine receptor gene (DRD2) in obesity with comorbid substance use disorder: A preliminary report. Pharmacogenetics, 6(4), 297-305.
5. Blum, K., Noble, E. P., Sheridan, P. J., Montgomery, A., Ritchie, T., Jagadeeswaran, P., Nogami, H., Briggs, A. H., & Cohn, J. B. (1990). Allelic association of human dopamine D2 receptor gene in alcoholism. Journal of the American Medical Association, 263(15), 2055-2060.
6. Blum, K., Sheridan, P. J., Wood, R. C., Braverman, E. R., Chen, T. J., Cull, J. G., & Comings, D. E. (1996). The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. Journal of the Royal Society of Medicine, 89(7), 396-400.
7. Brandon, T. H., Collins, B. N., Juliano, L. M., & Lazev, A. B. (2000). Preventing relapse among former smokers: A comparison of minimal interventions through telephone and mail. Journal of Consulting and Clinical Psychology, 68(1), 103-113.
8. Bunce, M., O'Neil, C. M., Barnardo, M. C., Krausa, P., Browning, M. J., Morris, P. J., & Welsh, K. I. (1995). Phototyping: Comprehensive DNA typing for HLA-A, B, C, DRB1, DRB 4, DRB 5 and DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens, 46, 355-367.
9. Comings, D., & Blum, K. (2000). Reward deficiency syndrome: Genetic aspects of behavioral disorders. Progress in Brain Research, 126, 325-341.
10. Comings, D., Ferry, L., Bradshaw-Robinson, S., Burchette, R., Chiu, C., & Muhleman, D. (1996). The dopamine D2 receptor (DRD2) gene: A genetic risk factor in smoking. Pharmacogenetics, 6(1), 73-79.
11. Comings, D. E., & MacMurray, J. P. (2000). Molecular heterosis: A review. Molecular Genetics and Metabolism, 71(1-2), 19-31.
12. Cooper, B. R., Hester, T. J., & Maxwell, R. A. (1980). Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): Evidence for selective blockade of dopamine uptake in vivo. Journal of Pharmacology and Experimental Therapeutics, 215(1), 127-134.
13. Cooper, B. R., Wang, C. M., Cox, R. F., Norton, R., Shea, V., & Ferris, R. M. (1994). Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology, 11(2), 133-141.
14. David, S. P., Johnstone, E., Griffiths, S. E., Murphy, M., Yudkin, P., Mant, D., & Walton, R. (2002). No association between functional catechol O-methyl transferase 1947A>G polymorphism and smoking initiation, persistent smoking or smoking cessation. Pharmacogenetics, 12(3), 265-268.
15. Dong, J., & Blier, P. (2001). Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology (Berlin), 155(1), 52-57.
16. Durcan, M. J., Deener, G., White, J., Johnston, J. A., Gonzales, D., Niaura, R., Rigotti, N., & Sachs, D. P. (2002). The effect of bupropion sustained-release on cigarette craving after smoking cessation. Clinical Therapeutics, 24(4), 540-551.
17. Fagerström, K. O. (1978). Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addictive Behaviors, 3(3-4), 235-241.
18. Faucette, S. R., Hawke, R. L., Lecluyse, E. L., Shord, S. S., Yan, B., Laethem, R. M., & Lindley, C. M. (2000). Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metabolism and Disposition, 28(10), 1222-1230.
19. Fiore, M. (2000). U.S. Public Health Service clinical practice guideline: Treating tobacco use and dependence. Respiratory Care, 45(10), 1200-1262.
20. Fryer, J. D., & Lukas, R. J. (1999). Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. Journal of Pharmacology and Experimental Therapeutics, 288(1), 88-92.
21. Fung, Y. K., Schmid, M. J., Anderson, T. M., & Lau, Y. S. (1996). Effects of nicotine withdrawal on central dopaminergic systems. Pharmacology, Biochemistry, and Behavior, 53(3), 635-640.
22. Glassman, A. H. (1993). Cigarette smoking: Implications for psychiatric illness. American Journal of Psychiatry, 150(4), 546-553.
23. Glynn, T., & Manley, M. W. (1989). How to help your patients stop smoking: A manual for physicians. (NIH Publication No. 89-3064). Bethesda, MD: Smoking, Tobacco, and Cancer Program, Division of Cancer Prevention and Control, National Cancer Institute, U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health.
24. Gonzales, D., Bjornson, W., Durcan, M. J., White, J. D., Johnston, J. A., Buist, A. S., Sachs, D. P., Rigotti, N. A., Niaura, R., Hays, J. T., & Hurt, R. D. (2002). Effects of gender on relapse prevention in smokers treated with bupropion SR. American Journal of Preventive Medicine, 22(4), 234-239.
25. Hays, J., Hurt, R. D., Rigotti, N. A., Niaura, R., Gonzales, D., Durcan, M. J., Sachs, D. P., Wolter, T. D., Buist, A. S., Johnston, J. A., & White, J. D. (2001). Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. A randomized, controlled trial. Annals of Internal Medicine, 135(6), 423-433.
26. Heath, A., Cates, R., Martin, N. G., Meyer, J., Hewitt, J. K., Neale, M. C., & Eaves, L. J. (1993). Genetic contribution to risk of smoking initiation: comparisons across birth cohorts and across cultures. Journal of Substance Abuse, 5(3), 221-246.
27. Hesse, L. M., Venkatakrishnan, K., Court, M. H., von Moltke, L. L., Duan, S. X., Shader, R. I., & Greenblatt, D. J. (2000). CYP2B6 mediates the in vitro hydroxylation of bupropion: Potential drug interactions with other antidepressants. Drug Metabolism and Disposition, 28(10), 1176-1183.
28. Hildebrand, B. E., Nomikos, G. G., Bondjers, C., Nisell, M., & Svensson, T. H. (1997). Behavioral manifestations of the nicotine abstinence syndrome in the rat: Peripheral versus central mechanisms. Psychopharmacology (Berlin), 129(4), 348-356.
29. Hughes, J., Hatsukami, D. K., Pickens, R. W., Krahn, D., Malin, S., & Luknic, A. (1984). Effect of nicotine on the tobacco withdrawal syndrome. Psychopharmacology (Berlin), 83(1), 82-87.
30. Hurt, R. D., Sachs, D. P., Glover, E. D., Offord, K. P., Johnston, J. A., Dale, L. C., Khayrallah, M. A., Schroeder, D. R., Glover, P. N., Sullivan, C. R., Croghan, I. T., & Sullivan, P. M. (1997). A comparison of sustained-release bupropion and placebo for smoking cessation. New England Journal of Medicine, 337(17), 1195-1202.
31. Hutchison, K., LaChance, H., Niaura, R., Bryan, A. D., & Smolen, A. (2002). The DRD4 VNTR polymorphism influences reactivity to smoking cues. Journal of Abnormal Psychology, 111(1), 134-143.
32. Hutchison, K. E., McGeary, J., Smolen, A., Bryan, A., & Swift, R. M. (2002). The DRD4 VNTR polymorphism moderates craving after alcohol consumption. Health Psychology, 21(2), 139-146.
33. Jonsson, E. G., Nothen, M. M., Grunhage, F., Farde, L., Nakashima, Y., Propping, P., & Sedvall, G. C. (1999). Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Molecular Psychiatry, 4(3), 290-296.
34. Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., Fiore, M. C., & Baker, T. B. (1999). A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. New England Journal of Medicine, 340(9), 685-691.
35. Killen, J. D., Fortmann, S. P., Newman, B., & Varady, A. (1991). Prospective study of factors influencing the development of craving associated with smoking cessation. Psychopharmacology (Berlin), 105(2), 191-196.
36. Koob, G. F. (2000). Neurobiology of addiction. Toward the development of new therapies. Annals of the New York Academy of Sciences, 909, 170-185.
37. Lerman, C., Roth, D., Kaufmann, V., Audrain, J., Hawk, L., Liu, A., Niaura, R., & Epstein, L. (2002). Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alcohol Dependence, 67(2), 219-223.
38. Lerman, C., Roth, D., Kaufman, V., Audrain, J., Main, D., Bowman, E. D., Lockshin, B., Boyde, N. R., & Shields, P. G. (1999). Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychology, 18(1), 14-20.
39. Lerman, C., Shields, P. G., Wileyto, E. P., Audrain, J., Pinto, A., Hawk, L., Krishnan, S., Niaura, R., & Epstein, L. (2002). Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics, 12(8), 627-634.
40. Madden, P., Heath, A. C., Pedersen, N. L., Kaprio, J., Koskenvuo, M. J., & Martin, N. G. (1999). The genetics of smoking persistence in men and women: A multicultural study. Behavioral Genetics, 29(6), 423-431.
41. Noble, E., Blum, K., Ritchie, T., Montgomery, A., & Sheridan, P. J. (1991). Allelic, association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Archives of General Psychiatry, 48(7), 648-654.
42. Peto, R. (2000, August). The hazards of smoking and the benefits of stopping. In Address to the 11th World Conference on Tobacco OR Health, Chicago. Chicago, IL: Brookings Institution Press.
43. Pohjalainen, T., Rinne, J., Någren, K., Lehikoinen, P., Anttila, K., & Syvälahti, E. K. G. (1998). The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Molecular Psychiatry, 3, 256-260.
44. Pomerleau, O. F., & Kardia, S. L. (1999). Introduction to the featured section: Genetic research on smoking. Health Psychology, 18(1), 3-6.
45. Robinson, T., & Berridge, K. C. (1993). The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Research and Brain Research Reviews, 18(3), 247-291.
46. Sanchez, C., & Hyttel, J. (1999). Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cellular and Molecular Neurobiology, 19(4), 467-489.
47. Shiffman, S., Johnston, J. A., Khayrallah, M., Elash, C. A., Gwaltney, C. J., Paty, J. A., Guys, M., Evoniuk, G., & DeVeaugh-Geiss, J. (2000). The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology (Berlin), 148(1), 33-40.
48. Shiffman, S., Paty, J. A., Guys, M., Kassel, J. A., & Hickcox, M. (1996). First lapses to smoking: Within-subjects analysis of real-time reports. Journal of Consulting and Clinical Psychology, 64(2), 366-379.
49. Slemmer, J. E., Martin, B. R., & Damaj, M. I. (2000). Bupropion is a nicotinic antagonist. Journal of Pharmacology and Experimental Therapeutics, 295(1), 321-327.
50. Stewart, J. J., Berkel, H. J., Parish, R. C., Simar, M. R., Syed, A., Bocchini, JA, Jr, Wilson, J. T., & Manno, J. E. (2001). Single-dose pharmacokinetics of bupropion in adolescents: Effects of smoking status and gender. Journal of Clinical Pharmacology, 41(7), 770-778.
51. Thompson, J., Thomas, N., Singleton, A., Piggott, M., Lloyd, S., Perry, E. K., Morris, C. M., Perry, R. H., Ferrier, I. N., & Court, J. A. (1997). D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: Reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics, 7(6), 479-484.
52. True, W., Heath, A. C., Sherrer, J. F., Waterman, B., Goldberg, J., Lin, N., Eisen, S. A., Lyons, M. J., & Tsuang, M. T. (1997). Genetic and environmental contributions to smoking. Addiction, 92(10), 1277-1287.
53. Wu, X., Hudmon, K. S., Detry, M. A., Chamberlain, R. M., & Spitz, M. R. (2000). D2 dopamine receptor gene polymorphisms among African-Americans and Mexican-Americans: A lung cancer case-control study. Cancer Epidemiology, Biomarkers, & Prevention, 9(10), 1021-1026.
54. Yudkin, P., Walton, R. T., Hey, K., Roberts, S. J., Welch, S. J., Johnstone, E. C., Griffiths, S. E., Jones, L. J., & Murphy, M. F. (2001, March 23-25). Is there an inherited basis for smoking behaviour? Paper presented at the 7th annual conference of the Society for Research on Nicotine and Tobacco, Seattle, WA.